Costs to medicaid of advancing immunosuppression in an urban HIV-infected patient population in Maryland

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue 3, 1997, Pages 223-231

  Moore, Richard D ^a   Chaisson, Richard E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Health care costs; Human immunodeficiency virus; Immunosuppression

Indexed keywords

ADULT; ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAID; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RETINITIS; T LYMPHOCYTE SUBPOPULATION; TERMINAL DISEASE; URBAN POPULATION;

CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030895251     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199703010-00005     Document Type: Article

References (50)

1. Bartlett J. Medical management of HIV infection. Glenview, Illinois: Physicians and Scientists Publishing Company, 1996.
2. Hardy AM, Rauch K, Echenberg D, Morgan WM, Curran JW. The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States. JAMA 1986;255:209-11.
3. Scitovsky AA, Cline M, Lee PR. Medical care costs of patients with AIDS in San Francisco. JAMA 1986;256:3103-9.
4. Andrulis DP, Beers VS, Bentley JD, Gage LS. The provision and financing of medical care for AIDS patients in U.S. public and private teaching hospitals. JAMA 1987;258:1343-6.
5. Solomon DJ, Hogan AJ, Bouknight RR, Solomon CT. Analysis of Michigan Medicaid costs to treat HIV infection. Public Health Rep 1989;104:416-24.
6. Kaplowitz LG, Turshen U, Myers PS, Staloch LA, Berry AJ, Settle JT. Medical care costs of patients with acquired immunodeficiency syndrome in Richmond. Virginia. Arch Intern Med 1988;148:1793-7.
7. Seage GR, Landers S, Lamb GA, Epstein AM. Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS). Am J Public Health 1990;80:835-9.
8. Hiatt RA, Quesenberry CP, Selby JV, Fireman BH, Knight A. The cost of acquired immune deficiency syndrome in Northern California. Arch Intern Med 1990;150:833-8.
9. Bennett CL, Cvitanic M, Pascal A. The costs of AIDS in Los Angeles. J Acquir Immun Defic Syndr 1991;4:197-203.
10. Hellinger FJ. The lifetime cost of treating a person with HIV. JAMA 1993;270:474-8.
11. Green J, Arno PS. The "medicaidization" of AIDS: trends in the financing of HIV-related medical care. JAMA 1990; 264:1261-6.
12. Diaz T, Chu SY, Conti L, et al. Health insurance coverage among persons with AIDS: results from a multistate surveillance project. Am J Public Health 1994;84:1015-8.
13. Bartnyska LM, Schactman M, Hidalgo J. Patterns in Maryland Medicaid enrollment among persons with AIDS. Inquiry 1995;32:184-96.
14. Centers for Disease Control. AIDS among racial/ethnic minorities - United States, 1993. MMWR 1994;43:644-55.
15. Centers for Disease Control and Prevention. AIDS among women - United States. MMWR 1995;44:81-4.
16. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. 1994;6(2):1-39.
17. Voelker R. States face rocky road to reform. JAMA 1995; 273(18):187-8.
18. Andrews R, Keyes M, Pine P. Longitudinal patterns of California Medicaid recipients with acquired immunodeficiency syndrome. Health Care Financing Rev 1991;13:1-12.
19. Solomon DJ, Hogan AJ. HIV infection treatment costs under Medicaid in Michigan. Public Health Rep 1992;107:461-8.
20. Merzel C, Crystal S, Sambamoorthi U, Karus D, Kurland C. New Jersey's Medicaid waiver for acquired immunodeficiency syndrome. Health Care Financing Rev 1992;13:27-44.
21. Markson LE, McKee L, Mauskopf J, Houchens R, Fanning TR, Turner BJ. Patterns of Medicaid expenditures after AIDS diagnosis. Health Care Financing Rev 1994;15:43-59.
22. Aseltyne WJ, Cloutier M, Smith MD. HIV disease and managed care: an overview. J Acquir Immun Defic Syndr 1995; 8(suppl 1):S11-S22.
23. Seage GR, Hertz T, Stone VE, Epstein AM. The effects of intravenous drug use and gender on the cost of hospitalization for patients with AIDS. J Acquir Immun Defic Syndr 1993: 6:831-9.
24. Bennett CL, Pascal A, Cvitanic M, Graham V, Kitchens A, DeHovitz JA. Medical care costs of intravenous drug users with AIDS in Brooklyn. J Acquir Immun Defic Syndr 1992; 5:1-6.
25. Hellinger FJ. The use of health services by women with HIV infection. Health Services Res 1993;28:543-61.
26. Stein MD. Injected-drug use: complications and costs in the care of hospitalized HIV-infected patients. J Acquir Immun Defic Syndr 1994;7:469-73.
27. Piette JD, Mor V, Mayer K, Zierler S, Wachtel T. The effects of immune status and race on health service use among people with HIV disease. Am J Public Health 1993;83:510-4.
28. Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in drug therapy for HIV disease in an urban community. N Engl J Med 1994;330:763-8.
29. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of HIV disease. N Engl J Med 1995;333:751-6.
30. U.S. Department of Labor. Monthly Labor Review, January 1996.
31. Conover WJ. Practical nonparametric statistics, 2nd ed. New York: John Wiley, 1980:213-343.
32. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
33. SAS. Version 6.11. Cary, North Carolina: SAS Institute, Inc., 1996.
34. Beck JR, Pauker SG. The Markov process in medical programs. Med Decis Making 1983;3:419-58.
35. Zucconi SL, Jacobson LP, Schrager NE, et al. Impact of immunosuppression on health care use by men in the Multicenter AIDS Cohort Study (MACS). J Acquir Immun Defic Syndr 1994;7:607-16.
36. Hurley SF, Kaldor JM, Gardiner S, Carlin JB, Assuncao RM, Evans DB. Lifetime cost of human immunodeficiency virus-related health care. J Acquir Immun Defic Syndr Human Retroviral 1996;12:371-8.
37. Fortgang I, Moore RD. Hospital admissions of HIV-infected patients from 1988 to 1992 in Maryland. J Acquir Immun Defic Syndr Hum Retroviral 1995;8:365-72.
38. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996;124:633-42.
39. + counts disease stages based on treatment protocols. J Acquir Immun Defic Syndr 1996;12:413-20.
40. Hellinger FJ. Forecasting the personal medical care costs of AIDS from 1988-1991. Public Health Rep 1988;103:309-319.
41. AIDS in New York State Through 1994. Albany, New York: New York Department of Health, 1996.
42. Bennett RL, Gilman SC, George L, Guze PA, Bennett CL. Improved outcomes in intensive care units for AIDS-related Pneumocystis carinii pneumonia: 1987-1991. J Acquir Immun Defic Syndr 1993;6:1319-21.
43. Gallant JE, McAvinue SM, Moore RD, Bartlett JG, Stanton DL, Chaisson RE. The impact of prophylaxis on outcome and resource utilization in Pneumocystis carinii pneumonia. Chest 1995;107:1018-23.
44. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of 3′-azido-3′-deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind placebo-controlled trial. N Engl J Med 1987;317: 185-91.
45. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. N Engl J Med 1990;322:941-9.
46. Moore RD, Hidalgo J, Baretta JC, Chaisson RE. Zidovudine therapy and health resource utilization in AIDS. J Acquir Immun Defic Syndr 1994;7:349-54.
47. Grumbach K, Keane D, Bindman A. Primary care and public emergency department overcrowding. Am J Public Health 1993;83:372-8.
48. Keruly JC, Chaisson RE, Moore RD. Comparison of progression to AIDS and survival in women and men from a large urban cohort [Abstract]. Washington, D.C.: HIV Infection in Women Conference, 1995.
49. Fleishman JA, Mor V, Laliberte LL. Longitudinal patterns of medical service use and costs among people with AIDS. Health Services Res 1995;30:403-24.
50. Anderson G, Chaulk P, Fowler E. Maryland: a regulatory approach to health system reform. Health Affairs 1993;12:40-7.